Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.
News|Videos|September 15, 2026
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
Author(s)Dr. Julia Rotow, Kaitlyn M. Le
Fact checked by: Spencer Feldman
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Advertisement
Advertisement
Dr. Julia Rotow, a thoracic medical oncologist at Dana-Farber Cancer Institute and global co-lead investigator of DESTINY-Lung04, discussed how the trial could change treatment sequencing for patients with newly diagnosed advanced or metastatic HER2-mutant lung cancer.
Related to this article
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Advertisement
Advertisement